Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

61.18 -0.85 (-1.37%)
Streaming Delayed Price Updated: 12:30 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260% ↗
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market. 
Via The Motley Fool
News headline image
Liquidia (LQDA) Q1 2026 Earnings Transcript ↗
Liquidia (LQDA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Liquidia Corp (NASDAQ:LQDA) Smashes Q1 Estimates as YUTREPIA Adoption Accelerates ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA): High Growth Momentum Setup Nears Breakout ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Presents a High-Growth Momentum and Technical Setup ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Shows High-Growth Momentum and Minervini Trend Alignment ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA) Reports Q4 2025 Profitability and Revenue Beat Driven by YUTREPIA Launch ↗
Via Chartmill
News headline image
Liquidia Q1 Earnings Call Highlights ↗
Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and... 
Via MarketBeat
Topics Earnings
News headline image
Liquidia Corporation Reports First Quarter 2026 Financial Results
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Corporation to Participate in Upcoming Investor Conferences
From Liquidia Technologies, Inc.
Via GlobeNewswire
Liquidia Corp (NASDAQ:LQDA) Identified as High-Growth Momentum Candidate by Minervini Trend Template ↗
Via Chartmill
News headline image
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million ↗
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Corporation to Participate in Upcoming Investor Conferences
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? ↗
This biotech focused on pulmonary therapies reported a notable insider sale amid strong share price gains and rising revenue. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M ↗
Biotech innovator Liquidia, focused on therapies for rare conditions, reported a notable insider sale amid strong recent share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares ↗
This biotech innovator in rare disease therapies reported significant insider selling amid a year of robust stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart ↗
Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms. 
Via The Motley Fool
Topics ETFs
News headline image
Liquidia (LQDA) Q4 2025 Earnings Call Transcript ↗
Liquidia (LQDA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Why Liquidia Stock Rocked the Market Today ↗
The company is clearly benefiting from the solid momentum of its newest drug on the market. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.